Foselutoclax is a small molecule commercialized by Unity Biotechnology, with a leading Phase II program in Diabetic Macular Edema. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Foselutoclax’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Foselutoclax is expected to reach an annual total of $25 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Foselutoclax Overview

UBX-1325 is under development for the treatment of ophthalmological diseases such as diabetic retinopathy, diabetic macular edema, choroidal neovascularization associated with age-related macular degeneration and neovascular  age related macular degeneration. The drug candidate is a backup to UBX1967 that acts by targeting BCL2. It is administered through intravitreal route.

Unity Biotechnology Overview

Unity Biotechnology develops and commercializes therapies for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. Unity Biotechnology’s product portfolio includes UBX0101, intended for musculoskeletal diseases; and UBX1325, for age-related diseases, including diabetic retinopathy and diabetic macular edema, glaucoma and age-related macular degeneration. It involves in developing products for idiopathic pulmonary fibrosis, systemic sclerosis, chronic obstructive pulmonary disease, cognition and kidney disease. The company works in collaboration with research institutions, academic, contract research organizations to develop its product portfolio. Unity Biotechnology is headquartered in south San Francisco, California, the US.
The operating loss of the company was US$45.2 million in FY2023, compared to an operating loss of US$57.4 million in FY2022. The net loss of the company was US$39.9 million in FY2023, compared to a net loss of US$44.5 million in FY2022.

For a complete picture of Foselutoclax’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.